Drug Trial Radar · NCT04302116
Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm
Last checked: Nov 19, 2026Latest source record: Aug 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
May 18, 2020
Primary completion
Jun 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Kullasate SakpichaisakulGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Mar 10, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 months, up to 14 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Infantile spasms (IS) are seizures associated with a severe infantile epileptic encephalopathy. Both cessation of spasms and electrographic response are necessary for the best neurodevelopmental outcomes. Adrenocorticotrophic hormone (ACTH), or prednisolone, or vigabatrin are considered the first-line treatment individually. However, ACTH expense and availability are the barriers in developing countries including Thailand. Vigabatrin, therefore, is the first recommended by Epilepsy Society of Thailand due to ACTH unavailability. Recently, combined steroid treatments (either ACTH or high dose prednisolone) with vigabatrin are superior in cessation of spasms compared to steroid treatment alone. Thus, this study is aimed to compare the efficacy of vigabatrin with high dose prednisolone combination therapy and vigabatrin alone.
Conditions
- Infantile Spasm
- West Syndrome
Interventions
Combination therapy with vigabatrin and prednisoloneDrug
High dose prednisolone (40 - 60 mg/day) for 1 month combined with vigabatrin treatment (50-150 mg/kg/day) twice daily for 4 months
Vigabatrin TabletsDrug
Vigabatrin (50-150 mg/kg/day) twice daily for 4 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cessation of spasmsTime frame: Assessed during Day 14 to Day 42 after treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Queen Sirikit National Institute of Child Health
Ratchathewi, Bangkok, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.